Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
The Lancet. Infectious Diseases
|
March 22, 2025
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
Tsiri Agbenyega, Anne E Schuind, Samuel Adjei, et al.
The Journal of Animal Ecology
|
June 9, 2022
The distribution of covert microbial natural enemies of a globally invasive crop pest, fall armyworm, in Africa: Enemy release and spillover events
Amy J Withers, Annabel Rice, Jolanda de Boer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 9, 2025
Prospects for cereal self-sufficiency in sub-Saharan Africa
Martin K van Ittersum, Seyyedmajid Alimagham, João Vasco Silva, et al.
Frontiers in Public Health
|
January 2, 2023
SARS-CoV-2 infections among asymptomatic individuals contributed to COVID-19 cases: A cross-sectional study among prospective air travelers from Ghana
Kwasi A Akowuah, Richard A Akuffo, Anthony T Boateng, et al.
Nature Communications
|
April 13, 2018
Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections
Angela M Early, Marc Lievens, Bronwyn L MacInnis, et al.
Human Vaccines & Immunotherapeutics
|
January 18, 2020
Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01<sub>E</sub> malaria vaccine in African children: a randomized trial
Innocent Valéa, Samuel Adjei, Effua Usuf, et al.
The Lancet. Global Health
|
September 20, 2025
Sustained efficacy of the RTS,S/AS01<sub>E</sub> malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial
Lawrence Osei-Tutu, Simon K Kariuki, Cynthia K Lee, et al.
Human Vaccines & Immunotherapeutics
|
April 10, 2018
Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial
Innocent Valéa, Samuel Adjei, Effua Usuf, et al.
The Journal of Infectious Diseases
|
March 4, 2024
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
Nelli Westercamp, Lawrence Osei-Tutu, Lode Schuerman, et al.
The Lancet. Infectious Diseases
|
June 26, 2022
Efficacy of RTS,S/AS01<sub>E</sub> malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
Aaron M Samuels, Daniel Ansong, Simon K Kariuki, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
The Lancet. Infectious Diseases
|
March 22, 2025
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
Tsiri Agbenyega, Anne E Schuind, Samuel Adjei, et al.
The Journal of Animal Ecology
|
June 9, 2022
The distribution of covert microbial natural enemies of a globally invasive crop pest, fall armyworm, in Africa: Enemy release and spillover events
Amy J Withers, Annabel Rice, Jolanda de Boer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 9, 2025
Prospects for cereal self-sufficiency in sub-Saharan Africa
Martin K van Ittersum, Seyyedmajid Alimagham, João Vasco Silva, et al.
Frontiers in Public Health
|
January 2, 2023
SARS-CoV-2 infections among asymptomatic individuals contributed to COVID-19 cases: A cross-sectional study among prospective air travelers from Ghana
Kwasi A Akowuah, Richard A Akuffo, Anthony T Boateng, et al.
Nature Communications
|
April 13, 2018
Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections
Angela M Early, Marc Lievens, Bronwyn L MacInnis, et al.
Human Vaccines & Immunotherapeutics
|
January 18, 2020
Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01<sub>E</sub> malaria vaccine in African children: a randomized trial
Innocent Valéa, Samuel Adjei, Effua Usuf, et al.
The Lancet. Global Health
|
September 20, 2025
Sustained efficacy of the RTS,S/AS01<sub>E</sub> malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial
Lawrence Osei-Tutu, Simon K Kariuki, Cynthia K Lee, et al.
Human Vaccines & Immunotherapeutics
|
April 10, 2018
Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial
Innocent Valéa, Samuel Adjei, Effua Usuf, et al.
The Journal of Infectious Diseases
|
March 4, 2024
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
Nelli Westercamp, Lawrence Osei-Tutu, Lode Schuerman, et al.
The Lancet. Infectious Diseases
|
June 26, 2022
Efficacy of RTS,S/AS01<sub>E</sub> malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
Aaron M Samuels, Daniel Ansong, Simon K Kariuki, et al.
Page
of 10